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ABSTRACT 
Spinal muscular atrophy (SMA) is a neuromuscular disease caused by loss of the survival 
motor neuron (SMN) gene. While there are currently two approved gene-based therapies for 
SMA, availability, high cost, and differences in patient response indicate that alternative 
treatment options are needed. Optimal therapeutic strategies will likely be a combination of 
SMN-dependent and -independent treatments aimed at alleviating symptoms in the central 
nervous system and peripheral muscles. Krüppel-like factor 15 (KLF15) is a transcription 
factor that regulates key metabolic and ergogenic pathways in muscle. We have recently 
reported significant downregulation of Klf15 in muscle of pre-symptomatic SMA mice. 
Importantly, perinatal upregulation of Klf15 via transgenic and pharmacological methods 
resulted in improved disease phenotypes in SMA mice, including weight and survival. In the 
current study, we designed an adeno-associated virus serotype 8 (AAV8) vector to 
overexpress a codon-optimised Klf15 cDNA under the muscle-specific Spc5-12 promoter 
(AAV8-Klf15). Administration of AAV8-Klf15 to severe Taiwanese Smn-/-;SMN2 or 
intermediate Smn2B/- SMA mice significantly increased Klf15 expression in muscle. We also 
observed significant activity of the AAV8-Klf15 vector in liver and heart.  AAV8-mediated 
Klf15 overexpression moderately improved survival in the Smn2B/- model but not in the 
Taiwanese mice. An inability to specifically induce Klf15 expression at physiological levels in 
a time- and tissue-dependent manner may have contributed to this limited efficacy. Thus, our 
work demonstrates that an AAV8-Spc5-12 vector induces high gene expression as early as 
P2 in several tissues including muscle, heart and liver, but highlights the challenges of 
achieving meaningful vector-mediated transgene expression of Klf15.  
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INTRODUCTION 
Spinal muscular atrophy (SMA) is a devastating childhood neuromuscular disease that leads 
to early death in the most severe cases 1,2. As an autosomal recessive disease, SMA is 
caused by loss of the survival motor neuron 1 (SMN1) gene due to either mutations or 
deletions 3. While a total deficiency in the SMN protein is embryonic lethal 4, humans have a 
duplicated copy of SMN1, termed SMN2 3, which allows for survival in the absence of the 
former. However, SMN2 contains a key C to T transition in exon 7 that leads to its excision in 
approximately 90% of the transcripts produced, generating a non-functional SMNΔ7 protein 
that is rapidly degraded 5,6. Importantly, the 10% of fully functional full length SMN protein 
produced from SMN2 is sufficient to allow survival, albeit not sufficient to prevent 
neuromuscular degeneration 7. 
The first genetic therapy for SMA, nusinersen/Spinraza™, was approved in December 2016 
by the Food and Drug Administration (FDA) and in June 2017 by the European Medicines 
Agency 8. This antisense oligonucleotide is delivered directly to the central nervous system 
(CNS) via a lumbar puncture and is aimed at promoting SMN2 exon 7 inclusion 9. 
Zolgensma® is a single, systemic of delivery of SMN1 via an adeno-associated virus 
serotype 9 (AAV9) gene therapy that received FDA approval in May 2019 10. Additional 
SMN-enhancing pharmacological compounds are also in the pipeline and anticipated to be 
approved for patient use in the near future 11. While the benefits of these SMN-dependent 
drugs are undeniably remarkable, it is appreciated that they unfortunately do not represent a 
cure and will have to be supported by additional non-CNS and -SMN therapeutic 
interventions to provide optimal care to all SMA patients 12–15. 
SMN-depleted skeletal muscle displays both cell-autonomous and non-autonomous defects 
16,17
 and is therefore an important therapeutic target for SMA. We have recently 
demonstrated the dysregulated expression of the transcription factor Krüppel-like factor 15 
(Klf15) in skeletal muscle of SMA mice during disease progression 18. KLF15 is crucial in the 
regulation of skeletal muscle metabolism and ergogenic properties 19–22. Specifically, we 
.CC-BY-NC 4.0 International licenseIt is made available under a 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/717785doi: bioRxiv preprint first posted online Jul. 28, 2019; 
4 
 
observed a significant downregulation of Klf15 expression in pre-symptomatic SMA mice and 
found that its neonatal upregulation via pharmacological (prednisolone) or transgenic 
(muscle-specific Klf15-overexpression) interventions significantly improved several disease 
phenotypes in SMA mice 18. However, prednisolone has pleiotropic activities and constitutive 
embryonic overexpression of Klf15 in skeletal muscle of SMA may have resulted in 
compensatory mechanisms 23. In this study, we thus set out to overexpress Klf15 in skeletal 
muscle of neonatal SMA mice via a self-complementary adeno-associated virus serotype 2/8 
and the Spc5-12 promoter. While this strategy led to substantial Klf15 expression in skeletal 
muscle of SMA mice and control littermates, there were no associated significant 
improvements in disease phenotypes. Nevertheless, AAV8-Klf15 injections resulted in 
pronounced expression as early as post-natal day 2 in several tissues including muscle, liver 
and heart, highlighting the potential of this specific viral construct for efficient perinatal 
delivery.  
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MATERIALS AND METHODS 
Animals 
Wild-type (WT) FVB/N mice were used for initial expression screening. The Taiwanese Smn-
/-;SMN2 (FVB/N background, FVB.Cg-Smn1tm1HungTg(SMN2)2Hung/J, RRID: J:59313) 24 
and the Smn2B/- 25 mice (generously provided by Dr Lyndsay M Murray, University of 
Edinburgh) were housed in individual ventilated cages (fed ad libitum, 12 hr light: 12 hr dark 
cycle) at the Biomedical Sciences Unit, University of Oxford, according to procedures 
authorized by the UK Home Office (Animal Scientific Procedures Act 1986). The viral 
constructs were diluted in sterile 0.9% saline and administered at the indicated dose at 
postnatal day (P) 0 by a facial vein intravenous injection 26. Litters were randomly assigned 
to treatment at birth. For survival studies, animals were weighed daily and culled at indicated 
time points or upon reaching their defined humane endpoint as set out by the Home Office 
Project Licence. For the Smn2B/- mice, weaned mice were given daily wet chow at the bottom 
of the cage to ensure proper access to food. Sample sizes were determined based on 
similar studies with SMA mice. 
 
Sc-AAV2/8-Spc5-12 constructs 
The generation of the self-complementary adeno-associated virus serotype 2/8 (scAAV2/8) 
vectors and quality control were performed by Atlantic Gene Therapies (Nantes, France). 
The synthetic Spc5-12 promoter 27 was used to drive the expression of eGFP or a codon-
optimised Klf15 sequence: 
agcgcttcaccacaggctcggccaggccagcatggttgatcatctgctgcctgtggacgagacattcagcagccctaagtgttct
gtgggctacctgggcgacagactggcctctagacagccttaccacatgctgccctctccaatcagcgaggacgactccgatgtgt
ctagcccttgtagctgtgcctctcctgacagccaggccttctgtagctgttactctgctggacctggacctgaggctcagggctctatc
ctggatttcctgctgagcagagctacactcggctctggcggaggatctggcggaatcggagattcttctggccctgtgacatgggg
ctcttggagaagggctagcgtgcccgtgaaagaggaacacttctgcttccctgagttcctgagcggcgacaccgatgacgtgtcc
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agacctttccagcctacactggaagagatcgaagagttcctcgaagagaacatggaagccgaagtgaaagaagcccctgag
aacggctcccgcgacctggaaacatgttctcagctgtctgccggctctcacagaagccatctgcaccctgaaagcgccggcag
agagagatgtacacctcctccaggtggaacatctggcggcggagcacaatctgctggcgaaggacctgctcatgatggacctg
tgcctgtgctgctgcaaatccagcctgtggctgtgaagcaagaggctggaacaggaccagcttctcctggacaggctcctgaatc
tgtgaaggtggcccagctgctggtcaacatccagggacaaacattcgccctgctgcctcaggtggtgcccagcagtaatctgaa
cctgcctagcaagttcgtgcggatcgctcctgtgccaatcgctgctaagcctatcggatctggctctcttggtcctggaccagctgga
ctgctcgtgggacagaagttccctaagaaccctgccgccgagctgctgaagatgcacaagtgtacattccccggctgctccaag
atgtataccaagtcctctcacctgaaggcccacctgagaaggcataccggcgagaagcctttcgcttgcacatggcctggatgtg
gctggcggttcagcagatctgatgagctgagcaggcaccgcagatctcacagcggagtgaagccataccagtgtcctgtgtgc
gagaagaagttcgccagaagcgaccacctgtccaagcacatcaaggtgcacagattccctagaagcagcagagccgtgcgg
gccatcaattgactgcagaagctt. 
 
C2C12 cell line 
C2C12 myoblast cells 28 were maintained in growth media consisting of Dulbecco’s Modified 
Eagle’s Media (DMEM) supplemented with 10% fetal bovine serum and 1% 
Penicillin/Streptomycin (all Life Technologies). For AAV transduction experiments, growth 
media was changed to differentiation media consisting of DMEM, 2% horse serum, and 1% 
Penicillin/Streptomycin (all Life Technologies). Cells were allowed to differentiate for 3 days, 
after which they were transduced with a MOI of 1E105. Cells were harvested 3 days post-
transduction for molecular analyses (flow cytometry or qPCR, as described below). 
 
qPCR 
Quadriceps muscles, liver, and heart were harvested at the indicated time points during 
disease progression and immediately flash frozen. RNA was extracted with the RNeasy 
MiniKit (Qiagen). For C2C12 cells, the media was removed and cells were washed with PBS 
before being directly lysed as per instructions within the RNeasy MiniKit (Qiagen). Reverse 
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transcription was performed using the High-Capacity cDNA Reverse Transcription Kit 
(ThermoFisher Scientific). qPCR was performed using SYBR green Mastermix 
(ThermoFisher Scientific) and primers for the codon-optimised Klf15 sequence (Forward: 
AGGACCTGCTCATGATGGAC; Reverse: TGTTTGTCCCTGGATGTTGA). RNA polymerase 
II polypeptide J (PolJ), was used as a validated stably expressed housekeeping gene 29 
(Forward: ACCACACTCTGGGGAACATC; Reverse: CTCGCTGATGAGGTCTGTGA). All 
primers were ordered from Integrated DNA Technologies. 
 
Flow cytometry 
Differentiated C2C12 cells 3 days post-transduction (AAV8-GFP, MOI of 1E105)  and 
untreated cells were trypsinized and washed in fluorescence-activated cell sorting (FACS) 
buffer (phosphate buffered saline (PBS) supplemented with 2% bovine serum albumin (BSA) 
and 0.05% sodium azide). Cells were pelleted by centrifugation at 300 x g for 5 minutes. The 
final cell pellet was resuspended in 200 μ of FACS buffer and the cell suspension was 
further diluted 1:2 in FACS buffer before detection in the Cytek DxP8 flow cytometer (Cytek® 
Biosciences). Cell viability was tested by adding 1 µl Sytox Red (Thermofisher) to the final 
cell suspension for 5 minutes at RT. The gating strategy included gating around the Sytox 
Red (RedFL1 channel) negative population following FCS/FCSW doublet exclusion. The 
remaining population was assessed for a GFP-shift by recording in the BluFL1 channel. A 
total of 10,000 cells was recorded for each sample replicate. Data was analysed using 
Flowjo 10 software (TreeStar Inc.). 
 
Immunocytochemistry and immunohistochemistry 
C2C12 cells transduced with the eGFP-expressing AAV vector were imaged live with a DM 
IRB microscope (Leica). 
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Quadriceps muscles were harvested at the indicated time points during disease progression, 
fixed in 4% paraformaldehyde, cryopreserved in 30% sucrose, and cryosectioned at a 
thickness of 12 μM. The sections were immunostained with chicken anti-GFP antibody 
(1:3000, Abcam) and detected with Alexa-488-conjugated anti-chicken secondary antibody 
(1:5000, Life technologies). Images were taken with an Olympus Fluoview FV1000 confocal 
microscope and processed with Fiji 30. 
 
Statistics 
All statistical analyses were performed using GraphPad Prism version 8.1.1 software. When 
appropriate, a Student’s unpaired two-tailed t test or a two-way ANOVA followed by an 
uncorrected Fisher's LSD multiple comparison test was used. Outliers were identified via the 
Grubbs' test and subsequently removed. Instances of outlier removal are detailed in the 
relevant figure legends. For the Kaplan-Meier survival analysis, a log-rank test was used. 
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RESULTS 
Muscle-specific Klf15 expression with a scAAV2/8-Spc5-12 viral vector 
To specifically induce Klf15 expression in skeletal muscle, we utilized a self-complementary 
adeno associated virus serotype 2/8 driven by the synthetic muscle-specific promoter Spc5-
12 27 (scAAV2/8-Spc5-12-Klf15, henceforth termed AAV8-Klf15). This combination of AAV 
and promoter has previously successfully been used for gene delivery to muscles for 
treatment of the muscle disorder Duchenne muscular dystrophy (DMD) 31. A control 
scAAV2/8-Spc5-12-GFP construct was also generated (henceforth termed AAV8-GFP). 
We first examined the transduction ability of the AAV8-GFP construct in differentiated 
C2C12 myoblasts 28. The cells were transduced with AAV8-GFP (multiplicity of infection 
(MOI) 1E105) for 3 days and assessed for GFP expression compared to untreated cells. 
Both flow cytometry and live imaging analyses confirm the abundant presence of GFP in 
AAV8-transduced cells (Fig 1a,b). Differentiated C2C12s transduced with AAV8-Klf15 (MOI 
1E105) demonstrate a significant increased expression of Klf15 mRNA compared to 
untreated cells (Fig 1c). 
 
Fig 1. Muscle-enhanced expression with the scAAV2/8-Spc5-12-Klf15 and-GFP (AAV8-
Klf15 and AAV8-GFP) viral vectors. a. Mean GFP fluorescence intensity (arbitrary units) 
determined by flow cytometry analysis in differentiated C2C12s, untreated or transduced 
with AAV8-GFP (MOI 1E105) for 3 days. Data are scatter plot and mean ± SEM, n = 3 wells 
per experimental group, unpaired t test, ****p<0.0001. b. Representative images (phase 
contrast and GFP fluorescent signal) of differentiated C2C12 cells 3 days post-transduction 
with AAV8-GFP (MOI 1E105). c. qPCR analysis of Klf15 mRNA expression in differentiated 
C2C12s 3 days post-transduction with AAV8-Klf15 (MOI 1E105) compared to untreated cells. 
Data are shown as scatter plot and mean ± SEM, n = 3 wells per experimental group, 
unpaired t test, ****p<0.0001. d. qPCR analysis of GFP mRNA expression in quadriceps 
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muscles of post-natal day (P) 2 and P7 wild type (WT) animals that received a facial 
intravenous injection of AAV8-GFP (1E11 vg/pup) at P0 compared to untreated WT mice. 
Data are scatter plot and mean ± SEM, n = 4–5 animals per experimental group, unpaired t 
test, *p = 0.028 (P2), **p = 0.0076 (P7). e. Representative images of cross-sections (P2) and 
longitudinal sections (P7) of quadriceps immunostained for GFP from P2 and P7 untreated 
WT animals and WT mice that received a facial intravenous injection of AAV8-GFP (1E11 
vg/pup) at P0. 
 
 
To determine if our constructs would also be active at early time points in muscle of neonatal 
mice, we administered AAV8-GFP (1E11 vg/pup) to P0 wild type (WT) pups via a facial vein 
intravenous injection 26. Quadriceps muscles were harvested from injected and non-injected 
WT littermates at P2 and P7. P2 represents the pre-symptomatic age at which we have 
observed a significant downregulation of Klf15 in the Taiwanese Smn-/-;SMN2 SMA mice 18,24 
while P7 is considered a late symptomatic time point. qPCR analysis shows a significant 
upregulation of GFP expression at both P2 and P7, albeit variable between animals, with 
increased levels at the later time point (Fig 1d). Immunohistochemistry of P2 and P7 
quadriceps also reveals a time-dependent increased expression of GFP in AAV8-treated 
animals compared to untreated littermates (Fig 1e). Combined, our experiments in C2C12s 
and WT mice demonstrate the ability of our viral vectors to induce Klf15 and GFP expression 
in differentiated skeletal muscle. 
 
Neonatal administration of AAV8-Klf15 to severe SMA mice does not improve weight 
or survival 
We next wanted to determine if increasing early postnatal Klf15 expression in the Smn-/-
;SMN2 SMA mice would influence disease progression. Administering 1E11 vg/pup of 
AAV8-Klf15 to P0 Smn-/-;SMN2 mice and Smn+/-;SMN2 control littermates revealed itself to 
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be toxic (spontaneous death without any impact on weight) to both genotypes (data not 
shown). Seeing as this dose was not harmful with AAV8-GFP, the adverse effects are most 
likely due to the supraphysiological levels of Klf15. We therefore reduced the AAV8-GFP and 
AAV8-Klf15 dose to 2E10 vg/pup for subsequent administrations, which still allowed for an 
age-dependent increased expression of GFP (Fig 2a) and Klf15 (Fig 2b), albeit with some 
variability between animals, in quadriceps of P2 and P7 Smn+/-;SMN2 and Smn-/-;SMN2 
mice. 
 
Fig 2. Perinatal administration of AAV8-Klf15 does not improve weight or survival of 
Smn-/-;SMN2 SMA mice. Post-natal day (P) 0 Smn-/-;SMN2 SMA mice and control 
littermates were either untreated or received a single facial vein intravenous injection of 
AAV8-GFP or AAV8-Klf15 (2E10 vg/pup). a. qPCR analysis of GFP mRNA expression in 
quadriceps of P2 and P7 untreated and AAV8-GFP-treated Smn+/-;SMN2 and Smn-/-;SMN2 
mice. Data are scatter plot and mean ± SEM, n = 2–6 animals per experimental group, two-
way ANOVA, **p<0.01, ***p<0.001. b. qPCR analysis of Klf15 mRNA expression in 
quadriceps of P2 and P7 untreated and AAV8-Klf15-treated Smn+/-;SMN2 and Smn-/-;SMN2 
mice. Data are scatter plot and mean ± SEM, n = 4–9 animals per experimental group, two-
way ANOVA, *p<0.05, ***p<0.001, ****p<0.0001. One outlier identified by the Grubbs’ test 
was removed from the P7 Smn-/-;SMN2 group c. Survival curves of untreated (n = 16), 
AAV8-GFP-treated (n = 9) and AAV8-Klf15-treated (n = 7) Smn-/-;SMN2 mice. Data are 
Kaplan-Meier survival curves, log-rank Mantel-Cox test, ns = not significant, **p = 0.0034 
(untreated vs AAV8-GFP), **p = 0.0048 (untreated vs AAV8-Klf15). d. Daily weights of 
untreated (n = 16), AAV8-GFP-treated (n = 9) and AAV8-Klf15-treated (n = 7) Smn-/-;SMN2 
mice. Data are mean ± SEM, two-way ANOVA, */^p<0.05, **/^^p<0.01, ***p<0.001, 
****p<0.0001. e. Survival curves of untreated (n = 12), AAV8-GFP-treated (n = 7) and AAV8-
Klf15-treated (n = 13) Smn+/-;SMN2 mice. Data are Kaplan-Meier survival curves, log-rank 
Mantel-Cox test, ns = not significant. f. Daily weights of untreated (n = 11), AAV8-GFP-
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treated (n = 8) and AAV8-Klf15-treated (n = 12) Smn+/-;SMN2 mice. Data are mean ± SEM, 
two-way ANOVA, */^/#p<0.05, **/^^p<0.01, ***/^^^p<0.001, ^^^^p<0.0001. g. Monthly 
weights of untreated (n = 11), AAV8-GFP-treated (n = 7) and AAV8-Klf15-treated (n = 13) 
Smn+/-;SMN2 mice. Data are mean ± SEM, two-way ANOVA, *p<0.05.  
 
 
In terms of effects on disease progression, we found that AAV8-Klf15-treated Smn-/-;SMN2 
mice survived longer than untreated Smn-/-;SMN2 (Fig 2c). However, AAV8-GFP-treated 
Smn-/-;SMN2 mice also display a moderately improved lifespan (Fig 2c), suggesting that the 
AAV construct itself has some beneficial physiological impact. Interestingly, we also 
observed that Smn-/-;SMN2 mice that received the AAV8-GFP weighed slightly more than 
AAV8-Klf15-treated and untreated Smn-/-;SMN2 (Fig 2d). 
We found no significant differences between the survival of untreated, AAV8-GFP-treated 
and AAV8-Klf15-treated Smn+/-;SMN2 mice (Fig 2e), although a small number of 
spontaneous deaths occurred in all cohorts. Similar to what we observed in the Smn-/-;SMN2 
mice, AAV8-GFP-treated Smn+/-;SMN2 mice weighed slightly more than untreated and 
AAV8-Klf15-treated Smn+/-;SMN2 mice during the P0–P21 pre-weaning phase (Fig 2f). 
However, this increased weight was not maintained post-weaning (Fig 2g). We did observe a 
small but significant increase in weight of AAV8-Klf15-treated Smn+/-;SMN2 mice at 6 
months of age. Thus, administering a perinatal injection of AAV8-Klf15 at a dose of 2E10 
vg/pup significantly increases Klf15 expression in skeletal muscle without having overt 
adverse or beneficial effects on survival. 
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Neonatal administration of AAV8-Klf15 to intermediate SMA mice slightly improves 
survival 
Due to the severe and rapid disease progression in the Smn-/-;SMN2 mice, they respond 
less favorably to non-SMN treatment strategies compared to the milder intermediate Smn2B/- 
mouse model 18,25,32,33. We therefore proceeded to evaluate the effect of AAV8-Klf15 in 
Smn2B/- mice and Smn2B/+ control littermates, following the same dosing regimen as in the 
severe SMA mice. Similar to what was observed in the Smn-/-;SMN2 mice, AAV8-GFP-
treated Smn2B/- mice also demonstrated a small but significant increase in survival compared 
to untreated Smn2B/- mice (Fig 3a). Interestingly, AAV8-Klf15-treated Smn2B/- mice had a 
significantly increased lifespan compared to both untreated and AAV8-GFP-treated Smn2B/- 
mice (Fig 3a). While AAV8-Klf15 did not influence the weight of Smn2B/- mice during the 
nursing period (up to P21), an increase in weight could be seen in the post-weaned mice 
(Fig 3b). However, that weight gain did not ultimately prevent an early death. Interestingly, 
AAV8-GFP-treated Smn2B/- mice were significantly heavier than untreated and AAV8-Klf15-
treated Smn2B/- mice (Fig 3b) between P13–21, again similar to what we found in the Smn-/-
;SMN2 mice. We did not observe any effects of AAV8-GFP or AAV8-Klf15 on the weights of 
pre-weaned Smn2B/- mice compared to untreated animals (Fig 3c). Thus, the AAV8-Klf15 
was slightly more beneficial in the intermediate Smn2B/- SMA mouse model than the severe 
Taiwanese Smn-/-;SMN2 mice, overall. 
 
Fig 3. Perinatal administration of AAV8-Klf15 slightly increases survival in Smn2B/- 
SMA mice. Post-natal day (P) 0 Smn2B/- SMA mice and control littermates were either 
untreated or received a single facial vein intravenous injection of AAV8-GFP or AAV8-Klf15 
(2E10 vg/pup). a. Survival curves of untreated (n = 15), AAV8-GFP-treated (n = 18) and 
AAV8-Klf15-treated (n = 11) Smn2B/- mice. Data are Kaplan-Meier survival curves, log-rank 
Mantel-Cox test, **p = 0.0021 (untreated vs AAV8-GFP), ****p<0.0001 (untreated vs AAV8-
Klf15), ***p = 0.0008 (AAV8-GFP vs AAV8-Klf15). b. Daily weights of untreated (n = 18), 
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AAV8-GFP-treated (n = 18) and AAV8-Klf15-treated (n = 11) Smn2B/- mice. Data are mean ± 
SEM, two-way ANOVA, */^/#p<0.05, **/^^p<0.01, ^^^p<0.001, ^^^^p<0.0001. c. Daily 
weights of untreated (n = 11), AAV8-GFP-treated (n = 9) and AAV8-Klf15-treated (n = 16) 
Smn2B/+ mice. Data are mean ± SEM, two-way ANOVA, ns = not significant. 
 
 
 
The AAV8-Spc5-12 construct also induces expression in heart and liver 
While the synthetic Spc5-12 promoter has been used for its enhanced activity in skeletal 
muscle 27,31, we wanted to determine if our AAV8 delivery system also induced expression in 
heart and liver, tissues in which Klf15 also plays key roles 34,35. We indeed observed 
significant increased expression of GFP and Klf15 mRNA in the livers of both P2 and P7 
AAV8-GFP- (Fig 4a) and AAV8-Klf15-treated (Fig 4b) Smn+/-;SMN2 and Smn-/-;SMN2 mice 
compared to untreated animals. This increase was approximately 15 times (GFP) and 10 
times (Klf15) higher than in skeletal muscle for both time points. Similarly, we find a 
significant upregulation of GFP and Klf15 mRNA in the hearts of AAV9-GFP- (Fig 4c) and 
AAV8-Klf15-treated (Fig 4d) P2 and P7 Smn+/-;SMN2 and Smn-/-;SMN2 mice compared to 
untreated animals. Surprisingly, the increase in heart was approximately 40 times (GFP) and 
50 times (Klf15) higher at P2 while in was approximately 70 times (GFP) and 10 times 
(Klf15) higher at P7 compared to skeletal muscle at those respective time points. Of note, 
there was some variability between animals within the same experimental group. Therefore, 
our results demonstrate that the activity of the AAV8-Spc5-12 vector is not exclusive to 
skeletal muscle. 
 
Fig 4. Perinatal administration of the AAV8-Spc5-12 construct induces high 
expression in liver and heart.  Post-natal day (P) 0 Smn-/-;SMN2 SMA mice and control 
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littermates were either untreated or received a single facial vein intravenous injection of 
AAV8-GFP or AAV8-Klf15 (2E10 vg/pup). a-b. qPCR analysis of GFP (a) and Klf15 (b) 
mRNA expression in quadriceps muscles of P2 and P7 untreated and AAV8-treated Smn+/-
;SMN2 and Smn-/-;SMN2 mice. Data are scatter plot and mean ± SEM, n = 2–6 animals per 
experimental group, two-way ANOVA, **p<0.01, ***p<0.001, ****p<0.0001. One outlier 
identified by the Grubbs’ test was removed from the P7 liver AAV8-Klf15 Smn-/-;SMN2 group. 
c-d. qPCR analysis of GFP (c) and Klf15 (d) mRNA expression in heart of P2 and P7 
untreated and AAV8-treated Smn+/-;SMN2 and Smn-/-;SMN2 mice. Data are scatter plot and 
mean ± SEM, n = 2–8 animals per experimental group, two-way ANOVA, **p<0.01, 
**p<0.01, ***p<0.001 ****p<0.0001. One outlier identified by the Grubbs’ test was removed 
from the P2 heart untreated Smn-/-;SMN2 group.  
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DISCUSSION 
We have recently demonstrated that Klf15 expression is significantly downregulated in 
muscle of pre-symptomatic SMA mice and that upregulating Klf15 expression via genetic 
(transgenic muscle-specific expression) or pharmacological (prednisolone) approaches 
results in improved disease phenotypes 18. Here, we evaluated the impact of specifically 
upregulating Klf15 in skeletal muscle in perinatal mice by driving its expression via an AAV8-
Spc5-12 vector. We find that while neonatal administration of the AAV8-Klf15 construct leads 
to significant increased levels of Klf15 in muscle, this has no overt effect on survival or 
weight gain in the severe Taiwanese SMA mice while we observe a small improvement in 
the lifespan of the intermediate Smn2B/- mice. 
The lack of significant impact of AAV8-Klf15 in severe SMA mice may be due to several 
compounding factors. While the levels of Klf15 expression achieved with AAV8-Klf15 are 
similar to the levels observed in transgenic SMA mice overexpressing muscle-specific Klf15 
at P2 (~ 5–10 fold greater than control littermates), the amounts measured in P7 AAV8-
Klf15-treated animals are significantly greater than the transgenic mice (~ 65–740 fold 
greater and ~ 30 fold greater, respectively, compared to control littermates) (Fig 2) 18. As 
Klf15 can display both atrophy-inducing 36 and ergogenic 19 properties in skeletal muscle in a 
dose-dependent manner 37, it is quite possible that the supraphysiological levels achieved 
with AAV8-Klf15 favor muscle wasting over growth. We also note significantly more 
variability in Klf15 levels in animals injected with the AAV8 construct compared to the 
transgenic mice (Fig 2) 18, which are most likely due to differential injection efficiencies 
and/or vector spread and could influence physiological outcomes. 
We have previously shown that administration of prednisolone to SMA mice also increases 
Klf15 levels in skeletal muscle of P2 pre-symptomatic animals (~ 6 fold greater than 
untreated controls) 18. However, this effect on Klf15 induction ceased at P7, specifically in 
SMA mice 18, suggesting that prednisolone-dependent benefits in symptomatic SMA mice 
may be due to KLF15-independent effects and/or that prednisolone-dependent Klf15 
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increase in P7 animals may be limited by compensatory inhibitory mechanisms due to 
already significantly increased Klf15 levels in symptomatic SMA mice compared to controls 
18
. It is therefore possible that an optimal strategy would be to conditionally increase Klf15 
expression in pre-symptomatic stages only, which is not easily achieved as the kinetics of 
AAV-mediated overexpression require several days for efficient transgene activity. To 
achieve optimal expression at early pre-symptomatic post-natal stages may therefore require 
pre-natal delivery. 
While our AAV8 construct was designed to overexpress Klf15 specifically in skeletal muscle, 
our analysis of heart and liver demonstrate significantly higher activity in these tissues (Fig 
4). KLF15 has well described roles in heart and liver 34,35, suggesting that its increased 
expression via our AAV8 construct, most likely also impacts the function of these tissues. 
SMA mice display several heart and liver pathologies 38,39, suggesting that aberrant KLF15 
levels may have non-intended organ-specific adverse effects, which most likely explain the 
spontaneous deaths observed in our mice treated with the high vector dose. Furthermore, 
we have previously reported increased levels of Klf15 in the liver and heart of symptomatic 
mice 18, which most likely reflect a pathological response. 
Surprisingly, the AAV8-GFP construct also demonstrated some non-negligible effects on 
disease phenotypes of SMA mice (Fig 3). While we cannot be certain as to why that is, we 
speculate that it may be related to possible effects on the immune system, similarly to 
previous reports for AAV8 vectors 40,41. Seeing as SMA mice have an altered immune 
response 42,43 and that inflammation can display both protective and adverse systemic 
properties 44, including the CNS 45 and muscle 46, it is possible that an activated immune 
response results in acute and/or intermittent benefits in AAV8-treated SMA animals. 
In summary, the limited impact of AAV8-Klf15 administration in SMA mice might be 
explained by several experimental conditions that most likely reduced our ability to increase 
Klf15 specifically in skeletal muscle at physiological levels and with the optimal timing, 
without influencing the function of other tissues and systems. In the experimental paradigms 
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tested here, the positive, albeit small, effect on survival and weight was restricted to the 
milder Smn2B/- SMA mouse model. 
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